Oumaima, Morocco

'We always have hope that things will be better in the future and that one day we will manage to find a final cure for MS. Until that time, we have to follow the latest research.'

Our application to the Essential Medicines List

Efforts to improve access to MS treatments continue

Brain volume changes may be key indicator for MS progression

New research suggests the rate of brain atrophy, or brain shrinkage, may be an important indicator of disease progression in MS.

First therapy to treat pediatric MS approved in US

Fingolimod has been approved by the US Food and Drug Administration (FDA) as a treatment for children and young people aged 10 years and older with relapsing MS

A new fingolimod-like drug is safe in people with relapsing-remitting MS

A phase II trial shows safety and efficacy of amiselimod

Rebound syndrome after stopping fingolimod

Researchers find that suddenly stopping fingolimod may lead to severe worsening of symptoms in MS

Alternative to natalizumab in people at risk of a brain infection

Swedish study favours rituximab over fingolimod for those at risk of progressive multifocal leukoencephalopathy

Natalizumab is more effective than fingolimod in reducing relapses

French researchers compare oral and injectable drugs for relapsing-remitting MS

New drug ozanimod could be an effective alternative to fingolimod

An international study looks at the safety and efficacy of a drug similar to fingolimod

Fingolimod is not effective in primary progressive multiple sclerosis

A new trial has failed to show Fingolimod has any effect of in primary-progressive MS

Recommended treatment after stopping natalizumab

Switching from natalizumab to an alternative drug may prevent disease reactivation

Switching to second-line disease-modifying drugs

Study shows that switching to natalizumab is more effective than switching to fingolimod

Long-term efficacy, safety and tolerability of fingolimod

Fingolimod is effective in reducing relapses and brain volume loss

Disappointing results from fingolimod trial in primary progressive MS

The results suggest that primary progressive and relapsing forms of MS have different underlying mechanisms

Underweight women on fingolimod at higher risk of lymphopenia

Underweight women and patients with low baseline lymphocyte counts should be monitored more closely